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Introduction: The aim of this study was to examine whether the cumulative inflammatory burden is associated
with an increase in arterial stiffness in a prospective cohort of psoriatic arthritis (PsA) patients.
Methods: In total, 72 PsA patients were followed for a median of 6.5 years. Cumulative inflammatory burden was
represented by the cumulative averages of repeated measures of erythrocyte sedimentation rate (ca-ESR) and
C-reactive protein (ca-CRP). Brachial-ankle pulse wave velocity (PWV) was measured at the last visit. We also included
47 healthy controls for PWV assessment.
Results: PWV was significantly higher in PsA patients compared with healthy controls after adjustment for age,
gender and body weight (1466 ± 29 cm/s versus 1323 ± 38 cm/s, P = 0.008). PsA patients were divided into two
groups based on whether their PWV value is ≥1450 cm/s (High PWV group, N = 38) or <1450 cm/s (Low PWV
group, N = 34). The High PWV group had a significantly higher ca-ESR (29 (19 to 44) versus 18 (10 to 32) mm/1st
hour, P = 0.005) and ca-CRP (0.7 (0.3 to 1.4) versus 0.4 (0.2 to 0.7) mg/dl, P = 0.029). Using regression analysis, high
ca-ESR (defined as ≥75th percentile: 37 mm/1st hour) was associated with a higher likelihood of being in the High
PWV group (odds ratio (OR): 9.455 (1.939 to 46.093), P = 0.005, adjusted for baseline clinical and cardiovascular risk
factors; and 9.111 (1.875 to 44.275), P = 0.006, adjusted for last visit parameters).
Conclusions: Cumulative inflammatory burden, as reflected by ca-ESR, was associated with increased arterial stiffness
in PsA patients even after adjustment for cardiovascular risk factors, emphasizing the important role of chronic
inflammation in accelerating the development of cardiovascular risks in PsA patients.Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory arth-
ritis associated with an increased risk of subclinical [1,2],
clinical cardiovascular disease (CVD) [3] and early car-
diovascular (CV) mortality [4]. Chronic inflammation
plays a pivotal role in the pathogenesis of subclinical
CVD in PsA patients [5,6]. Inflammation is involved in
foam cell formation, endothelial dysfunction and Th1
cytokine production, which leads to the development of
arterial dysfunction [7] and atherosclerotic plaque [8].
However, inflammatory markers including erythrocyte
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stated.failed to differentiate PsA patients with or without sub-
clinical atherosclerosis in cross-sectional studies [1,9],
most likely because PsA is a chronic relapsing condition
in which inflammation may fluctuate over time. The
chronic inflammatory burden may be better represented
by the cumulative average of inflammatory markers than
the measurement of these markers at a single time point.
Eder and colleagues have recently reported that in-
creased inflammatory burden over time, as reflected by
cumulative average of ESR, is associated with the extent
of atherosclerotic plaques in PsA patients from a pro-
spective cohort [10]. This association is attenuated after
adjustment for traditional CV risk factors. In patients
with rheumatoid arthritis (RA), a prospectively study
also demonstrated that higher average CRP levels are as-
sociated with incident or progressive plaque, but only inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Shen et al. Arthritis Research & Therapy  (2015) 17:75 Page 2 of 9patients with high CVD risk [11]. In RA, the average
CRP correlates with the presence of subclinical athero-
sclerosis measured by carotid intima-media thickness
(IMT) [12]. Also, the average CRP is associated with an
increased risk of CV events and mortality in patients
with long-standing RA [13]. Whether chronic inflamma-
tion can accelerate atherogenesis independently or
mediate it via adverse modification of CV risk factors re-
mains uncertain.
Arterial stiffness is an independent predictor of CV
events and mortality [14]. Pulse wave velocity (PWV) is
a measure of early structural vascular changes, which
is determined by the elasticity and other properties of
the artery, and is correlated with arterial distensibility
and stiffness. An increase in brachial-ankle PWV by
100 cm/s corresponds to an age-, sex-, and risk factor-
adjusted increase of 12% in total CV events, and 13%
in CV mortality, respectively [15]. By applying a cutoff
value of 1450 cm/s, brachial-ankle PWV was found to
discriminate normal subjects from those with CVD or
atherosclerotic risk factors with sensitivity of 62.1% and
specificity of 69.5% in a large-scale population-based
study involving 21,094 Chinese subjects [16]. Two pre-
vious case–control studies failed to find a correlation
between ESR or CRP and PWV in PsA patients [17,18].
However, these studies were limited by small sample
size and cross-sectional study design and were unable
to assess the effect of cumulative inflammation over
time. The effect of cumulative inflammatory burden in
arterial stiffness in patients with RA is controversial
[19,20]. Whether cumulative inflammatory burden over
time may affect arterial stiffness as assessed by PWV in
PsA has never been explored. We hypothesize that PsA
patients with higher cumulative inflammatory burden
(as measured by cumulative averages of the area under
the curve (AUC) for ESR and CRP) would have in-
creased arterial stiffness. In this study, we first com-
pared the arterial stiffness between PsA patients and
healthy controls. Second, we examined whether the cu-
mulative inflammatory burden over time is associated
with an increase in arterial stiffness in a prospective co-
hort of PsA patients.
Methods
Patients and healthy controls
Eighty-two PsA patients who participated in a prior sub-
clinical study of atherosclerosis in PsA [1] were recruited
for a PWV assessment between 2012 and 2013. Briefly,
all participants fulfilled the Classification of Psoriatic
Arthritis (CASPAR) criteria [21] and had been prospect-
ively followed at the rheumatology clinic of two regional
hospitals (The Prince of Wales Hospital and the Alice
Ho Miu Ling Nethersole Hospital) since 2006 to 2007
(baseline visit). Exclusion criteria at baseline includedovert CVD (including myocardial infarction, angina,
stroke, and transient ischemic attack), inability to pro-
vide informed consent, clinically significant renal disease
(serum creatinine level >270 mol/L), or pregnancy. Pa-
tients were assessed by rheumatologists every 4 to
6 months, which included a complete history, physical
examination and laboratory evaluation: 72 patients who
completed the last follow-up visit and had a successful
brachial-ankle PWV assessment were included in the
analysis.
We recruited 47 healthy controls from a broad
spectrum of hospital staff. None of the controls had a
known history of hypertension, diabetes, hyperlipidemia,
or overt CVD (including myocardial infarction, angina,
stroke, or transient ischemic attack), or family history of
CVD.
Ethics approval was obtained from the Ethics Committee
of The Chinese University of Hong Kong-New Territories
East Cluster Hospitals, and written informed consent was
obtained from all participants according to the Declaration
of Helsinki.
Clinical interview at baseline and last follow-up visit
Pain and physicians’ and patients’ global assessments
were evaluated using a 100-point visual analog scale,
where 0 indicated excellent well-being and 100 indicated
feeling extremely unwell. Physical examination included
recording the number of tender and swollen joints using
the 68 tender-joint/66 swollen-joint count, the presence
of dactylitis, and the number of permanently deformed
joints. The Health Assessment Questionnaire (HAQ)
was used to evaluate physical function [22], and the
Psoriasis Area and Severity Index (PASI) was used to
assess the extent of skin involvement [23]. Overall dis-
ease activity was assessed using the Disease Activity in
Psoriatic Arthritis (DAPSA) and Minimal Disease Activity
(MDA) scores [24]. Anthropomorphic measurements in-
cluding height, weight, and waist and hip circumference,
and two consecutive blood pressure (BP) readings in the
sitting position and heart rate were recorded. Other data
obtained from PsA patients through the interview and
chart review included smoking and drinking habits, his-
tory of diabetes, hypertension, hypercholesterolemia and
overt CVD. Drug history was retrieved from case notes or
elicited during the clinical assessment. All patients were
interviewed and examined using standardized data collec-
tion instruments.
Laboratory tests
Complete blood count, liver and renal function tests,
ESR and CRP were checked at every visit. Fasting blood
glucose, and lipid profile (total cholesterol (TC), low-
density lipoprotein-cholesterol (LDL), high-density
lipoprotein-cholesterol (HDL), and triglycerides) were
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flammation over time was represented by the cumu-
lative averages of ESR (ca-ESR) and CRP (ca-CRP).
Pulse wave velocity
Brachial-ankle PWV was assessed noninvasively in sub-
jects in the supine position by a dedicated tonometry
system (Non-Invasive Vascular Profile Device VP-2000;
Omron Healthcare, Inc, Bannockburn, IL, USA) as de-
scribed previously [25]. All PWV measurements were
performed twice at each side of the body by a single
skilled operator. The means of overall PWV measure-
ments were recorded. The intra-class correlation coeffi-
cient (ICC) for intraobserver reliability was 0.84 [26].
Statistical analysis
Results are expressed as mean ± SD or median (inter-
quartile range) as appropriate. Comparisons between
two groups were assessed using the Student’s t-test or
Mann–Whitney U-test for continuous variables and the
chi-square (χ2) test for categorical variables. Analysis of
covariance (ANCOVA) was used to compare means of
PWV between PsA and control subjects by adjusting for
parameters that were distributed differently between
groups. Spearman’s correlation was used to evaluate bi-
variate correlation. ca-ESR and ca-CRP were calculated
from the AUC of all available measurements divided by
the total number of months of follow-up. Univariate
analysis was performed to ascertain the association be-
tween clinical parameters and PWV. The cutoff value
for CV and atherosclerotic risk, which was derived from
the large-scale Chinese population-based study [16],
was used to divide the PsA patients into a high-PWV
group (≥1,450 cm/s) or low-PWV group (<1,450 cm/s).
Multivariable logistic regression analysis was used to de-
termine the independent predictor(s) for being in the
high-PWV group. All variables with P <0.1 in the univar-
iate analysis were included in the multivariate analysis.
All statistical analyses were conducted using IBM SPSS
Statistics Version 22 (IBM, Armonk, NY, USA). A min-
imal level of significance of P <0.05 is used.
Results
Clinical features of PsA patients
A total of 72 (36 male and 36 female) PsA patients were
included in the analysis. At baseline, the mean ± SD age
was 49.6 ± 11.7 years and the median (IQR) disease dur-
ation was 9.2 (2.4 to 14.1) years. The median follow-up
duration from baseline to the time of PWV assessment
(last visit) was 6.5 (range: 4.8 to 7.7) years. Table 1 sum-
marized the clinical features of the patients at baseline
and last visit. Compared with baseline, significant im-
provement in disease activity parameters (number of
tender and swollen joint counts, pain, DAPSA and CRP)and physical function (HAQ) were observed at the last
visit, although the damaged joint count increased. CV
risk factors remained stable except for systolic blood
pressure (SBP) and HDL levels decreased. More patients
were taking anti-hypertensive drugs, statins and biologic
disease modifying anti-rheumatic drugs (DMARDs) at
the last visit.
PWV in PsA patients and control subjects
The mean PWV in PsA patients and control subjects
were 1,533 ± 307 cm/s and 1,219 ± 157 cm/s, respectively
(P <0.001) (Figure 1A). The control subjects were signifi-
cantly younger (43.1 ± 10.2 years versus 55.9 ± 11.6 years,
P <0.001), had higher proportion of women (72.3%
versus 50.0%, P = 0.015) and a lower body weight
(58.2 ± 8.7 kg versus 65.7 ± 11.6 kg, P <0.001) at
PWV assessment compared with the PsA patients.
However, after adjustment for age, gender and body
weight, the adjusted mean PWV was still significantly
greater in PsA patients compared with control subjects
(1,466 ± 29 cm/s versus 1,323 ± 38 cm/s, P = 0.008)
(Figure 1B). If patients with hypertension, diabetes or
hyperlipidemia were excluded, the age, gender, and body
weight-adjusted mean for PsA patients (n = 20) and con-
trol subjects were 1,394 ± 46 and 1,248 ± 29 cm/s, re-
spectively (P = 0.013) (Figure 1C).
Association between traditional cardiovascular risk factors
and PWV
The associations between PWV and clinical features at
both baseline and the last visit (PWV assessment visit)
are shown in Table 2. At PWV assessment, patients in
the high-PWV group (n = 38) were significantly older,
had higher SBP and Framingham 10-year CVD risk
score, were more likely to have diabetes and hypertension,
and to be treated with anti-hypertensive drugs compared
with the low-PWV group (n = 34) (all P <0.05).
Association between disease-related parameters and PWV
Disease-related variables were compared between the
two PWV groups (Table 2). The high-PWV group had a
trend of longer disease duration (P <0.1). At baseline,
the high-PWV group had significantly higher ESR
levels compared with patients in the low-PWV group
(P = 0.048). At PWV assessment, the high-PWV group
had significantly higher damaged joint count, ESR and
CRP levels.
Association between cumulative inflammatory burden
and PWV
The median ca-ESR was 24 (12 to 38) mm/1st h and the
median ca-CRP was 0.6 (0.2 to 1.1) mg/dl in the PsA pa-
tients. There was a significant correlation between PWV
and ca-ESR (Spearman’s rho 0.390, P = 0.001) but not
Table 1 Clinical features at baseline and last visit in all PsA patients
Baseline Last visit P-value
Male gender, n (%) 36 (50.0%)
Age, years 49.6 ± 11.7 55.9 ± 11.6
Psoriatic arthritis (PsA) characteristics
PsA disease duration, years 9.2 (2.4 to 14.10) 15.7 (8.5 to 21.2)
Tender joint count, 0 to 68 2 (0 to 8) 1 (0 to 4) 0.033
Swollen joint count, 0 to 66 0 (0 to 3) 0 (0 to 1) 0.032
Damaged joint count, 0 to 68 2 (0 to 5) 2 (0 to 6) 0.031
Visual analog scale pain, 0 to 100 50 (30 to 66) 30 (20 to 58) 0.001
Patients’ global assessment, 0 to 100 50 (30 to 60) 40 (20 to 60) 0.298
Physicians’ global assessment, 0 to 100 20 (0 to 30) 20 (5 to 35) 0.683
Psoriasis Area and Severity Index, 0 to 72 2.6 (0.9 to 7.5) 1.8 (0.4 to 6.3) 0.309
Health assessment questionnaire, 0 to 3 0.38 (0.12 to 0.94) 0.25 (0 to 0.69) 0.043
Minimal disease activity, n (%) 16 (22.2%) 14 (19.4%) 0.539
Disease Activity in Psoriatic Arthritis, 0 to 164 16 (8 to 21) 11 (6 to 16) 0.010
Erythrocyte sedimentation rate, mm/1st h 23 (10 to 37) 18 (8 to 34) 0.357
C-reactive protein, mg/dl 0.4 (0.2 to 1.3) 0.3 (0.1 to 0.7) 0.016
Cardiovascular risk factors
Body weight, kg 65.2 ± 12.0 65.7 ± 11.6 0.436
Body height, cm 161 ± 8
Systolic blood pressure, mmHg 136 ± 22 127 ± 15 <0.001
Hypertension, n (%) 36 (50.0%) 44 (61.1%) 0.555
Diabetes, n (%) 16 (44.4%) 16 (44.4%) 1.000
Framingham 10-year CVD risk >10%, n (%) 30 (41.7%) 36 (50.0%) 0.316
Total cholesterol, mmol/L 5.1 ± 0.9 4.9 ± 0.8 0.073
High-density lipoprotein cholesterol, mmol/L 1.6 ± 0.5 1.4 ± 0.4 <0.001
Triglycerides, mmol/L 1.5 ± 0.9 1.5 ± 0.9 0.558
Fasting glucose, mmol/L 5.5 ± 1.3 5.5 ± 1.6 0.861
Medications, n (%)
Anti-hypertensive drugs 20 (27.8%) 42 (58.3%) <0.001
Statins 1 (1.4%) 14 (19.4%) <0.001
Nonsteroidal anti-inflammatory drugs 33 (45.8%) 31 (43.1%) 0.737
Steroids 4 (5.6%) 3 (4.2%) 0.999
Disease-modifying antirheumatic drugs 36 (50.0%) 40 (55.6%) 0.504
Biologics 0 (0%) 11 (15.4%) 0.001
Values are presented as number (percentage), median (interquatile range) or mean ± SD. CVD, cardiovascular disease.
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significantly higher ca-ESR (31 (21 to 44) versus 17
(10 to 30) mm/1st h, P <0.001) and ca-CRP (0.7 (0.3
to 1.4) versus 0.4 (0.2 to 0.7) mg/dl, P = 0.029) com-
pared with the low-PWV group (Figure 2).
The association between the cumulative inflammatory
burden and PWV was assessed by regression analysis
(Table 3). High ca-ESR (defined as ≥75th percentile:
37 mm/1st h) was associated with a higher likelihood ofbeing in the high-PWV group after adjustment for other
clinical and CV risk factors at baseline (OR 9.455
(95% CI 1.939, 46.093), P = 0.005) or last visit (OR 9.111
(95% CI 1.875, 44.275), P = 0.006) (Table 3). In contrast,
high ca-CRP (defined as ≥75th percentile 1.2 mg/dl) was
not associated with a higher likelihood of being in the
high-PWV group (Table 3).
Older age was the other independent risk factor associ-
ated with a higher likelihood of being in the high-PWV
Figure 1 Pulse wave velocity (PWV) in control subjects and patients with psoriatic arthritis (PsA). (A) Unadjusted mean in control subjects
(n = 47) and all PsA patients (n = 72). (B) Mean adjusted by age, gender and body weight in control subjects and all PsA patients. (C) Mean
adjusted by age, gender and body weight in control subjects and PsA patients without hypertension, diabetes or hyperlipidemia (n = 20).
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1.058, 1.223), P <0.001; adjusted for last-visit parameters:
OR 1.135 (95% CI 1.056, 1.219), P = 0.001).
Discussion
This is the first study to assess the association between
cumulative inflammatory burden and arterial stiffness in
PsA patients. High cumulative inflammatory burden as
reflected by the ca-ESR was a predictor for higher PWV
independently of traditional CV risk factors and other
disease activity parameters. We also confirmed that
PWV is increased in PsA patients compared with
healthy control subjects in a larger cohort.
We have demonstrated a significant correlation between
ca-ESR and PWV (P = 0.001) and a marginally significant
correlation between ca-CRP and PWV (P = 0.061), sug-
gesting that chronic inflammation may have a causative
role in the development of arterial dysfunction in PsA pa-
tients. These results were consistent with previous find-
ings that cumulative inflammatory burden (ca-ESR) was
associated with increased aortic augmentation index in
RA [19] and severity of carotid plaque in PsA [10]. One
previous study reported that PWV associated with current
CRP levels, but not with historical measures of cumulative
ESR inflammatory burden in RA [20]. However, this study
excluded patients with hypercholesterolemia and hyper-
tension, and current smokers. In the current study
ca-ESR, ca-CRP and single measurements of ESR and
CRP at PWV assessment were associated with high
PWV in the univariate analysis. Nonetheless, only ca-
ESR was independently associated with high PWV in
multivariate analysis after adjusting for other traditional
CV risk factors and disease-related parameters, indicat-
ing that the cumulative inflammatory burden may better
explain increased arterial stiffness than transient inflam-
matory status.
Different from ca-ESR, ca-CRP was not associated
with PWV in multiple regression. A previous study from
Eder et al. reported no association between ca-CRP
and atherosclerosis in patients with PsA [10] whileGiles et al. [11] reported that higher ca-CRP levels
were associated with incident or progressive plaque,
primarily in patients with elevated CVD risk in patients
with RA. These seemingly contradictory findings may be
explained by the relatively low levels of chronic inflam-
mation that are commonly found in PsA compared with
RA. A high-sensitivity (hs) CRP assay may be more in-
formative, but was not available in our study. Serial mon-
itoring of inflammatory markers including hsCRP should
be considered in PsA patients.
Damaged joint count at the last visit was also associ-
ated with increased PWV in the univariate analysis.
Indeed, damaged joint count could also represent the
cumulative inflammatory burden and was found to be
independently associated with atherosclerosis in RA
[27]. However, the significance of damaged joint count
was lost after adjusting for ca-ESR and other CV risk
factors in PsA patients.
We also confirmed that arterial stiffness is increased in
PsA patients. PWV was significantly higher in PsA pa-
tients after adjustment for age, gender and body weight,
and even after PsA patients with hypertension, diabetes
or hyperlipidemia were excluded. This is consistent with
other studies with smaller case numbers that measured
arterial stiffness by aortic PWV [17,18]. Costa et al. [17]
reported increased PWV in 20 PsA patients compared
with 20 controls. Soy et al. [18] also showed that PWV
was higher in 9 PsA patients compared with 39 controls.
In a previous study involving 73 PsA patients and 50
healthy controls, a significant increase in augmentation
index was noticed, indicating impairment of both
macrovascular and microvascular functions [28].
Although increased overall mortality in PsA patients
has been reported in some [29-32] but not all [33,34]
studies, previous data have consistently indicated an in-
creased susceptibility to CVD and related mortality in
PsA patients [3,35]. Our results indicated that the in-
creased CVD and related mortalities may be partly me-
diated by increased arterial stiffness through persistent
chronic inflammation. Inflammation accelerates subclinical
Table 2 Clinical features at baseline and last follow-up visit in patients in the high and low pulse-wave
velocity (PWV) groups
Baseline Last visit
Low PWV High PWV P-value Low PWV High PWV P-value
Male gender, n (%) 17 (50.0%) 19 (50.0%) 1.000 17 (50.0%) 19 (50.0%) 1.000
Age, years 43.3 ± 10.2 55.2 ± 10.0 <0.001 49.6 ± 10.1 61.6 ± 9.9 <0.001
Psoriatic arthritis (PsA) characteristics
PsA disease duration, years 7.6 ± 7.0 10.7 ± 7.5 0.073 13.9 ± 7.2 17.1 ± 7.8 0.075
Tender joint count, 0 to 68 2 (0 to 6) 3 (0 to 8) 0.551 1 (0 to 3) 1 (0 to 5) 0.248
Swollen joint count, 0 to 66 0 (0 to 2) 1 (0 to 3) 0.827 0 (0 to 1) 0 (0 to 1) 0.376
Damaged joint count, 0 to 68 1 (0 to 3) 2 (0 to 6) 0.118 0 (0 to 4) 4 (0 to 8) 0.010
Visual analog scale pain, 0 to 100 40 (20 to 60) 50 (30 to 70) 0.212 30 (20 to 50) 30 (20 to 60) 0.964
Patients’ global assessment, 0 to 100 50 (20 to 60) 50 (40 to 60) 0.258 50 (20 to 60) 33 (20 to 60) 0.654
Physicians’ global assessment, 0 to 100 10 (0 to 20) 20 (5 to 30) 0.462 19 (6 to 35) 20 (7 to 30) 0.399
Psoriasis Area and Severity Index, 0 to 72 2.6 (1.0 to 7.3) 3.0 (0.7 to 7.7) 0.879 1.8 (0.6 to 5.4) 1.7 (0.3 to 7.4) 0.879
Health assessment questionnaire, 0 to 3 0.25 (0.13 to 0.63) 0.56 (0.13 to 1.00) 0.120 0.13 (0 to 0.50) 0.38 (0 to 1.13) 0.146
Minimal disease activity, n (%) 10 (29.4%) 6 (15.8%) 0.165 6 (17.6%) 8 (21.1%) 0.715
Disease Activity in Psoriatic Arthritis, 0 to 164 14 (7 to 19) 17 (12 to 22) 0.132 11 (7 to 15) 12 (5 to 18) 0.827
Erythrocyte sedimentation rate, mm/1st h 16 (7 to 34) 27 (13 to 56) 0.048 11 (5 to 22) 29 (13 to 56) <0.001
C-reactive protein, mg/dl 0.3 (0.1 to 1.2) 0.5 (0.2 to 1.3) 0.527 0.2 (0.1 to 0.5) 0.4 (0.2 to 0.8) 0.023
Cardiovascular risk factors
Body weight, kg 66.1 ± 12.4 64.4 ± 11.8 0.540 68.1 ± 12.0 63.6 ± 11.0 0.099
Body height, cm 161 ± 8 161 ± 9 0.891
Systolic blood pressure, mmHg 132 ± 23 140 ± 21 0.113 121 ± 13 132 ± 16 0.002
Hypertension, n (%) 10 (29.4%) 26 (68.4%) 0.001 15 (44.1%) 29 (76.3%) 0.005
Diabetes, n (%) 3 (8.8%) 13 (34.2%) 0.010 3 (8.8%) 13 (34.2%) 0.010
Framingham 10-year CVD risk >10%, n (%) 8 (23.5%) 22 (57.9%) 0.003 9 (26.5%) 27 (71.1%) <0.001
Total cholesterol, mmol/L 5.1 ± 0.9 5.1 ± 1.0 0.814 5.0 ± 1.0 4.8 ± 0.7 0.468
High-density lipoprotein cholesterol, mmol/L 1.6 ± 0.5 1.6 ± 0.5 0.782 1.5 ± 0.4 1.4 ± 0.4 0.467
Triglycerides, mmol/L 1.4 ± 0.7 1.6 ± 1.1 0.285 1.3 ± 0.8 1.5 ± 1.0 0.363
Fasting glucose, mmol/L 5.3 ± 1.6 5.7 ± 1.0 0.227 5.2 ± 1.0 5.6 ± 1.9 0.287
Medications, n (%)
Anti-hypertensive drugs 3 (8.8%) 17 (44.7%) <0.001 14 (41.2%) 28 (73.7%) 0.005
Statins 0 (0%) 1 (2.6%) 1.000 7 (20.6%) 7 (18.4%) 0.817
Nonsteroidal anti-inflammatory drugs 13 (38.2%) 20 (52.6%) 0.221 16 (47.1%) 15 (39.5%) 0.516
Steroids 2 (5.9%) 2 (5.3%) 0.999 1 (2.9%) 2 (5.3%) 0.999
Disease-modifying antirheumatic drugs 15 (44.1%) 21 (55.3%) 0.345 18 (52.9%) 22 (57.9%) 0.673
Biologics 0 (0%) 0 (0%) N.S. 7 (20.6%) 4 (10.5%) 0.236
Variables with P-values <0.1 (values in bold text) were candidates for multivariate analysis. Values are presented as number (percentage), median (interquatile range),
or mean ± SD.
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the traditional CV risk factors [10]. In contrast, the associ-
ation between cumulative inflammation and arterial stiff-
ness was independent of traditional CV risk factors such as
age, hypertension and diabetes. This may suggest that
inflammation-induced arterial dysfunction is probably an
early phase in the development of atherogenesis, andhence, PWV is a more sensitive marker reflecting changes
in predominantly macrovascular functions in patients with
rheumatic disease and chronic inflammation, compared to
arterial remodeling as reflected by increased IMT and
plaques.
PsA is associated with reduced levels of endothelial
progenitor cells (EPCs) and impaired EPC function,
Figure 2 Cumulative inflammatory burden and pulse wave velocity (PWV). Cumulative average of erythrocyte sedimentation rate (ca-ESR)
and C-reactive protein (CRP) in the low PWV group (PWV <1,450 cm/s, n = 34) and the high-PWV group (PWV ≥1,450 cm/s, n = 38).
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Inflammatory cells such as macrophages and poly-
morphonuclear neutrophils produce a variety of matrix
metalloproteinases (MMPs), which can alter the balance
of elastin/collagen [37]. Chronic inflammation may also
induce oxidative stress [7]. All these changes will lead to
arterial stiffening. Inflammation also interacts with other
important pathways such as advanced glycation end
products (AGEs), which can irreversibly bind to colla-
gens, resulting in stiffer AGE-linked collagen [38,39].
Moreover, AGEs can also promote inflammatory re-
sponse through binding to the receptor (RAGE) and
subsequently increase arterial stiffness [40,41]. TNF-α is
a key cytokine involved in the pathogenesis of PsA [42],
which can induce neutrophil chemotaxis, macrophage
activation and superoxide production. This results in
endothelial inflammation and dysfunction, and may con-
tribute to the development of arterial damage [43]. Data
from a non-randomized case–control study in patients
with inflammatory arthritis (RA, PsA and ankylosing
spondylitis) showed that long-term use of anti-TNF-α
therapy may result in a significant improvement in PWV
compared to the non-treated group [44]. Whether effect-
ive suppression of inflammation can improve arterialTable 3 Association between cumulative inflammatory
burden and high-PWV group by multivariable logistic
regression
Modela Factors Odds ratio 95% CI P-value
Baselineb High cumulative ESRd 9.455 1.939, 46.093 0.005
High cumulative CRPe 1.736 0.294, 10.268 0.543
Last visitc High cumulative ESRd 9.111 1.875, 44.275 0.006
High cumulative CRPe 0.888 0.088, 9.007 0.920
aAdjusted for parameters at baseline or last follow up. bParameters entered:
age, psoriatic arthritis (PsA) duration, hypertension, diabetes, Framingham risk
score, use of anti-hypertension drugs, high erythrocyte sedimentation rate (ESR)d,
cumulative average (ca)-ESRd and ca-C-reactive protein (CRP)e. cParameters
entered: age, PsA duration, body weight, systolic blood pressure, hypertension,
diabetes, damaged joints count, use of anti-hypertension drugs, Framingham
risk score, high ESRd and CRPe, high ca-ESRd and ca-CRPe. dDefined as ≥75th
percentile: 37 mm/1st h. eDefined as ≥75th percentile: 1.2 mg/dl.stiffness in PsA should be explored in future clinical
trials.
The strength of our study was the inclusion of a large
prospective cohort with long-term follow up. Patients
with CV risk factors were not excluded so that our re-
sults can be generalized to the usual PsA patient popula-
tion. Our study also has a few limitations. First, our
results may not be applicable to PsA patients from other
ethnic backgrounds. Second, the outcome of this study
(PWV) is only a surrogate of clinical CV events. In pa-
tients with PsA or RA, there are virtually no data to sug-
gest whether PWV is a good surrogate of future CVD
events. Third, arterial stiffness was assessed by brachial-
ankle PWV but not the gold standard, carotid-femoral
PWV. However, brachial-ankle PWV is highly correlated
with carotid-femoral PWV and may provide qualitatively
similar information [45]. Fourth, only baseline and last-
visit clinical and traditional risk factors were adjusted
for. With regards to the association between cumulative
inflammatory burden and arterial stiffness, we have only
addressed the role of cumulative averages of ESR and
CRP. Unfortunately, we did not have data on other disease
activity measures, for example, DAPSA and MDA during
all the visits. It would be of interest for a future study to in-
clude a measure such as average mean DAPSA, or to de-
termine whether achieving MDA for a prolonged period of
time could be a potential predictor of arterial stiffness. Last
but not least, baseline PWV measurement was not avail-
able to assess the relationship between cumulative inflam-
matory burden or the effect of treatment and the changes
in arterial stiffness. Further prospective studies should be
conducted to address this issue.
Conclusions
In conclusion, PsA patients have increased arterial stiffness
compared with healthy control subjects. Cumulative in-
flammatory burden contributes to the increased arterial
stiffness independent of traditional CV risk factors, sug-
gesting that increasing arterial stiffness may be one of the
mechanisms linking inflammation and CVD in PsA.
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